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Abstract
Background: In idiopathic pulmonary fibrosis loss of alveolar epithelium induces inflammation of the pulmonary
tissue followed by accumulation of pathogenic myofibroblasts leading eventually to respiratory failures. In animal
models inflammatory and resident cells have been demonstrated to contribute to pulmonary fibrosis. Regenerative
potential of pulmonary and extra-pulmonary stem and progenitor cells raised the hope for successful treatment
option against pulmonary fibrosis. Herein, we addressed the contribution of lung microenvironment and prominin-
1+ bone marrow-derived epithelial progenitor cells in the mouse model of bleomycin-induced experimental
pulmonary fibrosis.
Methods: Prominin-1+ bone marrow-derived epithelial progenitors were expanded from adult mouse lungs and
differentiated in vitro by cytokines and growth factors. Pulmonary fibrosis was induced in C57Bl/6 mice by
intratracheal instillation of bleomycin. Prominin-1+ progenitors were administered intratracheally at different time
points after bleomycin challenge. Green fluorescence protein-expressing cells were used for cell tracking. Cell
phenotypes were characterized by immunohistochemistry, flow cytometry and quantitative reverse transcription-
polymerase chain reaction.
Results: Prominin-1+ cells expanded from healthy lung represent common progenitors of alveolar type II epithelial
cells, myofibroblasts, and macrophages. Administration of prominin-1+ cells 2 hours after bleomycin instillation
protects from pulmonary fibrosis, and some of progenitors differentiate into alveolar type II epithelial cells. In
contrast, prominin-1+ cells administered at day 7 or 14 lose their protective effects and differentiate into
myofibroblasts and macrophages. Bleomycin challenge enhances accumulation of bone marrow-derived prominin-
1+ cells within inflamed lung. In contrast to prominin-1+ cells from healthy lung, prominin-1+ precursors isolated
from inflamed organ lack regenerative properties but acquire myofibroblast and macrophage phenotypes.
Conclusion: The microenvironment of inflamed lung impairs the regenerative capacity of bone marrow-derived
prominin-1+ progenitors and promotes their differentiation into pathogenic phenotypes.
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Introduction
Any tissue injury triggers inflammation, a complex
pathophysiological process, supposed to attenuate injury,
and to induce reparative processes. However, exaggerated
inflammatory responses may exacerbate tissue damage,
and result in excessive scarring further compromising
organ function. Idiopathic pulmonary fibrosis (IPF) is a
lung disease of unknown origin characterized by loss of
lung epithelial cells and pathological parenchymal tissue
remodelling, which results in accumulation of myofibro-
blasts, distortion of lung architecture, and eventually
respiratory failure [1]. Prognosis of IPF patients is poor
and effective therapeutic options are lacking [2].
Bleomycin-induced experimental pulmonary fibrosis is
the best-characterized animal model in use today [3].
Intratracheal instillation of bleomycin results in oxidative
damage to the alveolar epithelium and the recruitment of
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inflammatory cells. After resolution of the acute inflam-
mation, a chronic fibrotic process develops, which is
characterized by replacement of extracellular matrix by
fibrillar collagen and collagen-producing fibroblasts and
myofibroblasts. However, the molecular and cellular
mechanisms remain unclear.
Formation of type I collagen-producing, alpha smooth
muscle actin (aSMA)-positive myofibroblasts is a hall-
mark of pulmonary fibrosis. Despite decades of extensive
research, the origin of pulmonary myofibroblasts remains
elusive. Transformation of parenchymal epithelial cells
into myofibroblasts through epithelial-to-mesenchymal
transition is currently considered as a major process in
the development of pulmonary fibrosis [4,5]. However,
other studies point to stromal fibroblasts and bone mar-
row-derived cells as important sources of pulmonary
myofibroblasts [5-7]. Of note, in bleomycin-induced
experimental pulmonary fibrosis pathological fibroblasts
originate from different cellular sources [8].
Stem and progenitor cells represent a potentially
attractive treatment option against pulmonary fibrosis.
Several studies reported that lungs indeed contain pools
of endogenous pulmonary stem and progenitor cells
[9-11]. Furthermore, bone marrow-derived stem and
progenitor cells isolated from the lung [11,12] or from
other tissues [13-15] have the capacity to differentiate
into pulmonary epithelial cells. In addition, these cells
exhibit anti-inflammatory properties when administrated
early at the onset of the disease [12,16]. Nevertheless,
bone marrow-derived cells contribute only marginally to
lung regeneration [17,18] and we do not know yet, how
the specific microenvironment of the diseased lungs
alters fate and function of endogenous or therapeutically
administered stem and progenitor cells.
Prominin-1 (CD133) is a membrane-associated glyco-
protein present on hematopoietic stem and progenitor
cells [19,20]. Recently, we have described bone marrow-
derived lung resident prominin-1+ epithelial progenitors
with immunosuppressive capacity and their ability to dif-
ferentiate into alveolar type II epithelial cells [12]. Herein,
using a mouse model of bleomycin-induced experimental
lung injury we analysed the properties of the prominin-1+
epithelial progenitor cells in the lungs undergoing fibrotic
remodelling.
Material and Methods
Mice
C57Bl/6 mice and C57Bl/6-enhanced green fluorescent
protein (EGFP) transgenic mice (EGFP under control of b-
actin promoter) were purchased from Jackson Laboratory.
All animal experiments were conducted in accordance
with institutional guidelines and Swiss federal law and
were approved by the local authorities.
Generation of bone marrow chimera
5-7-week-old C57Bl/6 mice were lethally irradiated with
two doses of 6.5 Gy using a Gammatron (Co-60) system
and reconstituted with 2x107 donor bone marrow cells
from C57Bl/6-EGFP mice.
Induction of bleomycin-induced lung fibrosis and
treatment protocols
7-9-week-old C57Bl/6 or 11-13-week-old C57Bl/6-EGFP
chimera mice were anesthetized and intratracheally
injected with 0.05 U/mouse of bleomycin (Blenoxane,
Axxora-Alexis) as described [12]. In the respective
experiments, the animals received intratracheally 2 × 105
prominin-1+ cells 2h, 24h, 3d, 7d or 14d after bleomycin
instillation.
Cell culture
Cells were isolated from mouse lungs as described
previously [12]. Prominin-1+ cells were expanded in the
culture expansion medium (CEM; Additional file 1). In the
respective experiments, magnetic cell sorting using anti-
prominin-1-PE antibody (eBioscience) and anti-PE mag-
netic beads (Miltenyi) was used to enrich population of
prominin-1-expressing cells. To generate single cell
derived clones, 1-5 prominin-1+/EGFP+ cells were co-pla-
ted with prominin-1+/EGFP- feeder cells derived from the
healthy lung, and cultured for 2-3 weeks. Type II lung
alveolar epithelial differentiation was induced in the pre-
sence of the modified Small Airway Growth Medium
(SAGM; Cambrex) as described previously [12]; macro-
phage differentiation with 10 ng/mL macrophage-colony
stimulating factor (M-CSF, PeproTech); and fibroblast
differentiation with 10 ng/mL TGF-b (PeproTech) as
described before [21].
Reverse transcription and quantitative polymerase chain
reaction
RNA isolation and cDNA synthesis were performed as
described [22]. cDNA was amplified using the Power
SYBR Green PCR Master Mix (Applied Biosystems) and
oligonucleotides complementary to transcripts of the ana-
lyzed genes (Additional file 1).
Histology, immunocytochemistry and phagocytosis assay
Formalin-fixed, paraffin-embedded lung sections were
stained with hematoxylin and eosin for histological analysis
and with Masson’s trichrome staining for detection of col-
lagen fibers. Immunofluorescence analysis was performed
on frozen tissue sections and cells cultured on gelatin-
coated cover slips as described previously [12]. For promi-
nin-1 detection, frozen sections and cultured cells were
stained with the appropriate primary and followed with
secondary antibody (Additional file 1) prior to fixation with
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4% paraformaldehyde. Phagocytosis activity assay was
performed using the Alexa Fluor 488- or Texas Red-conju-
gated E. coli BioParticles (Invitrogen) according to manu-
facture’s recommendations.
Western-blot
Prominin-1+ cells were challenged with TGF-b (Pepro-
Tech) for 1, 6 and 24 hours. Control cells were cultured
in the absence of TGF-b Cell lysates were blotted and
incubated with appropriate antibodies (Additional file 1).
Flow cytometry
Cells were filtered through 70-μm nylon mesh filter,
stained for 30 minutes on ice with the appropriate antibo-
dies (Additional file 1), and analyzed on a CyAN ADP
(Dako-Cytomation) using FlowJo 8.7.3 software (TreeStar).
Statistics
Normally distributed data were compared using Student
t test or 1-way ANOVA followed by Bonferroni’s post-
test. Statistical analysis was conducted using Prism 4
software (GraphPad Software). Differences were consid-
ered as statistically significant for p < 0.05.
Results
Prominin-1+ expression characterizes epithelial
progenitors with multilineage differentiation capacity
We have previously demonstrated that bone marrow-
derived prominin-1+ cells expanded from healthy lung
explants represent progenitors of alveolar type II epithelial
cells [12]. In order to investigate if these prominin-1+ pro-
genitors differentiate into other cell types typically
observed in IPF, such as myofibroblasts and macrophages,
we expanded prominin-1+ cells from lung tissue in the
culture expansion medium (CEM) [12]. Expanded promi-
nin-1+ cells were negative for fibronectin (Figure 1A) and
other lineage-specific markers (data not shown), but
expressed CD45, c-kit, Sca-1 and Cxcr4 [12]. Next, we
sorted prominin-1-expressing cells and induced differen-
tiation towards type II pneumocytes, fibroblasts and
macrophages. Two weeks of culture in the modified Small
Airway Growth Medium (SAGM) resulted in formation of
pulmonary type II cells positive for surfactant protein-C
(SP-C; Figure 1B) as described [12]. In contrast, prominin-
1+ cells cultured in the presence of TGF-b differentiated
into fibronectin- and collagen I-producing fibroblast
(Figure 1C). Furthermore, addition of M-CSF to the
culture medium resulted in the formation of F4/80+
macrophages (Figure 1D).
Next, we addressed whether prominin-1+ cells repre-
sent a common progenitor for alveolar type II epithelial
cells, fibroblasts and macrophages. We expanded promi-
nin-1+ cells from lung explants of C57Bl/6-EGFP mouse
and plated 1-5 sorted EGFP+/prominin-1+ cells on non-
Figure 1 Lung-derived prominin-1+ cells turn into alveolar type
II epithelial cells, fibroblasts or macrophages after exposure to
different cytokines and growth factors. Expansion of cells from
the healthy lung explants in the culture expansion medium (CEM)
resulted in round, semi-adherent prominin-1-positive cells and
fibronectin-positive feeder layer (A, left). Harvested cells contained
mostly prominin-1-positive cells (A, right). Further, prominin-1-
positive cells were isolated using magnetic cell sorting and cultured
in the presence of different cytokines and growth factors. Prominin-
1+ cells cultured in the Small Airway Growth Medium (SAGM) for 14
days became surfactant protein-C (SP-C)-positive and prominin-1-
negative (B). Prominin-1+ cells cultured in the presence of TGF-b for
14 days lost prominin-1 expression, but instead produced
fibronectin and collagen I (C). Exposure of prominin-1+ cells to M-
CSF for 7 days resulted in formation of E.coli phagocytising F4/80-
positive cells (D). DAPI visualized cell nuclei. Bars = 20 μm.
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transgenic lung-derived feeder layer. After 14 days, we
observed single cell-derived EGFP+ colonies (Figure 2A).
Thereafter, co-cultures containing the single EGFP+
clone were divided into three different conditions stimu-
lating the lineage differentiation described above. EGFP+
cells differentiated into SP-C-positive type II pneumo-
cytes in the SAGM medium (Figure 2B), phagocyting
macrophages after exposure to M-CSF (Figure 2C), and
fibronectin-positive fibroblasts in response to TGF-b
(Figure 2D). We differentiated successfully 10 single cell-
derived clones. Taken together, these data demonstrate
that all three phenotypes can originate from a single
prominin-1+ progenitor. Thus, prominin-1 expression on
bone marrow-derived cells in the adult mouse lung is
specific for multilineage progenitors.
Bleomycin-induced pro-fibrotic pulmonary
microenvironment affects the fate of prominin-1+ cells
Given the high in vitro plasticity of prominin-1+ progeni-
tors, we tested how changes in the pulmonary microen-
vironment, which parallels fibrosis progression affect
their differentiation capacity in vivo within the affected
organ. Thus, we expanded cells from healthy lung of
C57Bl/6-EGFP+ mouse and instilled sorted prominin-1+
progenitors intratracheally 2h and 7d after bleomycin
challenge to C57Bl/6 recipients. Lungs of recipient mice
were analyzed 1 or 2 weeks after engraftment of the
EGFP+ cells. Injection of prominin-1+/EGFP+ cells 2h
after bleomycin instillation protected from pulmonary
inflammation and fibrosis at day 7 (not shown; [12]). At
this time point, we found some EGFP+ cells positive for
SP-C (Figure 3A), but nearly all were negative for the
myofibroblast-specific marker aSMA (Figure 3B). In con-
trast, prominin-1+/EGFP+ cells administrated to lungs
with active inflammation (7d after bleomycin instillation)
failed to express SP-C (Figure 3C), and mostly lost pro-
minin-1 expression (Figure 3D), but instead were positive
for aSMA (Figure 3E) and F4/80 (Figure 3F) within the
lung tissue analysed at day 21. Taken together, the speci-
fic microenvironment of the inflamed or fibrotic lung
determines the fate of transplanted multilineage promi-
nin-1+ progenitors.
Next, we analyzed how prominin-1+ cells affect bleomy-
cin-induced pulmonary fibrogenesis at different time
points of the disease progression. We administrated pro-
minin-1+ progenitors 2h, 24h, 3d, 7d and 14d following
bleomycin instillation and analyzed the extent of pulmon-
ary fibrosis at day 21. Histological analysis of lung sections
revealed that prominin-1+ progenitors are only protective
if they were injected within 2 h after bleomycin instillation
(Figure 4A, B; Additional file 1, Figure S1). In contrast,
prominin-1+ progenitors delivered after 24h, 3d, 7d or 14d
failed to attenuate bleomycin-induced fibrosis (Figure 4C-
F; Additional file 1, Figure S1). These findings indicate
that the changing pulmonary microenvironment at differ-
ent stages of pulmonary fibrosis affects the anti-inflamma-
tory properties of prominin-1+ cells.
Bleomycin promotes the accumulation of prominin-1+
progenitors in the injured lung
Inflammation mobilizes and activates local or exogenous
stem and progenitor cells. We therefore investigated
whether bleomycin instillation promotes the accumulation
of bone marrow-derived prominin-1+ progenitors in the
lung. So far, we have identified two distinct populations of
prominin-1 expressing cells in the healthy lung. Bone
marrow-derived prominin-1+lo progenitors were identified
as CD45-expressing cells with non-polarized membrane
distribution of the prominin-1 antigen and represent
about 7% of total prominin-1+ cells in healthy lung tissue
[12]. After bleomycin application, we observed increasing
proportions of CD45 expression within the whole promi-
nin-1+ cell population (Figure 5A). 14 days after bleomycin
instillation prominin-1+/CD45+ cell subset increased about
three fold compared to unaffected lungs (Figure 5B).
Furthermore, immunofluorescence analysis revealed
increased amount of cells with non-polarized prominin-1
localization on the cellular membrane during the inflam-
matory phase (d7) and accumulation of aSMA+ myofibro-
blasts during disease progression (Additional file 1, Figure
S2). Increased bone marrow-derived prominin-1+ progeni-
tors within the inflamed and fibrotic lungs suggest an
active contribution of this cell subpopulation to the devel-
opment of bleomycin-induced experimental pulmonary
fibrosis.
Bone marrow-derived cells enhance bleomycin-induced
experimental pulmonary fibrosis
Accumulation of aSMA+ and collagen I+ myofibroblasts
is a hallmark of pathological remodelling in pulmonary
fibrosis. Next, we analyzed the contribution of bone mar-
row-derived cells to regenerative SP-C+ alveolar type II
epithelial cells and pathological aSMA+ myofibroblasts in
our model. We lethally irradiated C57Bl/6 mice and
reconstituted them with C57Bl/6-EGFP syngeneic bone
marrow. Six weeks after bone marrow reconstitution, we
found no EGFP+ cells co-expressing aSMA or SP-C in
the lung of the chimeric mice (Figure 6A-B; d0). After
bleomycin instillation, acute lung inflammation devel-
oped (d7), and at this stage we observed no evident
aSMA and SP-C expression in EGFP+ cells (Figure 6C,
D). Instead, accumulated EGFP+ inflammatory cells
expressed prominin-1 (around 30-40%; Additional file 1,
Figure S3A). Analysis of fibrotic lungs (d21) demon-
strated that around some EGFP+ cells became aSMA+
myofibroblasts, but not SP-C+ type II epithelial or b-
tubulin IV-expressing cells (Figure 6E-F; Additional file
1, Figure S3B) in the chimeric mice. aSMA+ fibroblasts
Blyszczuk et al. Respiratory Research 2011, 12:126
http://respiratory-research.com/content/12/1/126
Page 4 of 13
Figure 2 Lung-derived prominin-1+ cells represent a common progenitor of alveolar type II epithelial cells, fibroblasts and
macrophages. Prominin-1-positive cells were isolated from lungs of C57Bl/6-EGFP mouse. One EGFP-expressing prominin-1+ cell co-cultured
with cells from healthy lungs for 14 days in the CEM proliferated and generated EGFP-positive single cell-derived clone (A). Co-culture containing
the EGFP-positive single cell-derived clone were split and cultured under conditions stimulating different lineage differentiation. After 7-14 days,
EGFP-expressing cells were positive for SP-C in the SAGM (B), phagocyted E.coli after treatment with M-CSF (C), and were positive for fibronectin
in the presence to TGF-b (D). DAPI visualized cell nuclei. Bars = 20 μm.
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contain around 25-30% of EGFP-expressing cells (calcu-
lation not shown). Of note, pulmonary fibrosis in chi-
meric mice was comparable to C57Bl/6 mice (Additional
file 1, Figure S4). These findings indicate that in mouse
model of bleomycin-induced experimental pulmonary
fibrosis, bone marrow represents one of the cellular
sources for progenitor cells differentiating into myofibro-
blasts, but not type II pneumocytes.
Figure 3 Differentiation of prominin-1+ progenitors is stage-specific in bleomycin-challenged mice. Expanded EGFP+ prominin-1-positive
cells were isolated using magnetic cell sorting and transplanted into C57Bl/6 mice by intratracheal injection 2 hours or 7 days after bleomycin
challenge. Some of engrafted EGFP+ cells injected 2 hours after bleomycin treatment were SP-C-positive (A), but nearly all were negative for
aSMA 7 days after transplantation (B). Instead, EGFP+/prominin-1+ cells transplanted 7 days after bleomycin treatment (into the lung with
ongoing inflammation) and analyzed at day 21 were negative for SP-C (C), rarely positive prominin-1 (D), but some expressed aSMA (E) and F4/
80 (F). DAPI visualized cell nuclei. Bars = 20 μm.
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Prominin-1+ progenitors isolated from diseased lungs
display impaired in vitro regenerative potential
Next, we addressed the differentiation potential of promi-
nin-1+ progenitors during acute pulmonary inflammation.
We injected intratracheally bleomycin and, after 7 days,
sorted prominin-1+ cells from the inflamed lung
and expanded them in the CEM medium for 2-3 weeks.
This resulted in the expansion of small, round, highly
Figure 4 Attenuation of bleomycin-induced pulmonary fibrosis by prominin-1+ cells is stage-specific. Expanded prominin-1-positive cells
were isolated using magnetic cell sorting and transplanted into recipient mice by intratracheal injection at different time points after bleomycin
instillation. Lung sections were analyzed 21 days after bleomycin instillation by hematoxylin and eosin (H&E) for excessive non-parenchymal
infiltrates and Masson’s trichrome staining for collagen I deposition (blue). Control mice injected with bleomycin developed severe pulmonary
fibrosis (A). Administration of prominin-1+ cells 2 hours after bleomycin treatment protected the mice from fibrosis (B). Mice receiving prominin-1+
cells 24 hours (C), 3 days (D), 7 days (E) or 14 days (F) after bleomycin challenge failed to protect from pulmonary fibrosis. Magnifications: x100.
Microphotographs from one independent experiment are shown for each time point. For quantification see in Additional file 1, Figure S1.
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Figure 5 Bone marrow-derived prominin-1+ cells accumulate in the lung of bleomycin-instilled mice. Flow cytometry analysis of CD45
expression gated on prominin-1+ cells in the lung before (d0) and 7, 14, 21 and 30 days after bleomycin instillation. Density plots and
histograms demonstrate one representative out of five independent experiments (A, B). Quantification of flow cytometry analysis of prominin-1
+/CD45+ cells out of all analyzed cells in the lung tissue following bleomycin treatment (C). FS - forward scatter, Iso- isotype control. Bars
represent mean ± SD from 5 individual lung tissues.
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Figure 6 Bone marrow-derived myofibroblasts contribute to bleomycin-induced pulmonary fibrosis. C57Bl/6 mice were lethally irradiated
and reconstituted with bone marrow of syngeneic C57Bl/6-EGFP animals. 6 weeks after bone marrow reconstitution, some of the chimeric mice
received bleomycin to induce pulmonary fibrosis. In the lung of unchallenged chimeric mice, EGFP-positive cells were negative for SP-C (A) and
aSMA (B). In the chimeric mice 7 days after bleomycin instillation, EGFP-positive cells accumulated in the inflamed lung tissue but were negative
for SP-C (C) and aSMA (D). 21 days after treatment with bleomycin, some EGFP+ cells were positive for aSMA (F), but not for SP-C (E). DAPI
visualized cell nuclei. Bars = 20 μm.
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proliferating cells expressing prominin-1, CD45, c-kit and
CXCR4 antigens, but not type II epithelial cell-, macro-
phage- or myofibroblast-specific markers (Figure 7A). Of
note, all prominin-1+ cells following the in vitro culture
co-expressed CD45 (Figure 7A), but not b-tubulin IV- a
marker of bronchial epithelial cells (not shown). Thus,
prominin-1+ cells expanded from healthy and inflamed
lungs show the same phenotypic characteristic [12]. Then,
we addressed whether prominin-1+ cells expanded from
inflamed lungs differentiate into myofibroblast, macro-
phage, and type II pneumocyte cell lineages in vitro. Cells
were again sorted for prominin-1 prior to differentiation
induction. In the presence of TGF-b prominin-1+ cells
significantly up-regulated Fn1, Col1a1 and Acta2 mRNA
expression, lost prominin-1 expression and acquired fibro-
nectin-positive myofibroblast phenotype (Figure 7B).
Furthermore, TGF-b stimulation activated Smad path-
way on prominin-1+ progenitors as demonstrated by
phosphorylation of Smad2 (P-Smad2; Additional file 1,
Figure S5). In the presence of M-CSF, on the other hand,
prominin-1+ cells lost prominin-1 expression and became
F4/80+ macrophages (Figure 7C). However, prominin-1+
cells expanded from inflamed lungs failed to up-regulate
Sftpc expression and did not differentiate towards SP-C-
positive type II alveolar epithelial cells upon culture in
the SAGM medium (Figure 7D). This is in strong contrast
to prominin-1+ progenitors derived from the healthy
lungs (Figure 7D). Taken together, our data indicate that
inflammatory processes in the lung impair regenerative
capacity of bone marrow-derived prominin-1-expressing
progenitors.
Discussion
We recently identified a population of bone marrow-
derived lung resident prominin-1+ epithelial progenitor
cells with the capacity to differentiate into alveolar type II
epithelial cells in vitro and in vivo [12]. Here, we report
that these cells represent a common progenitor for type II
epithelial cells, macrophages and myofibroblasts. Further-
more, we show that lineage commitment of prominin-1+
progenitors critically depends on epigenetic stimuli, such
as cytokines or microenvironment in the lung.
Several studies reported the ability of bone marrow-
derived cells to become lung epithelial cells in mouse
[11-14] and in humans [23,24]. This notion nourished
the hope for rapid development of regenerative cell-
based therapies using easily accessible hematopoietic
stem and progenitor cells. However, recent observations
from transgenic animal models clearly demonstrated that
naturally occurring regeneration from any cells of hema-
topoietic origin is minimal after lung injury [17,18].
Our study proposes a potential mechanism explaining
this discrepancy. We suggest that pathophysiological
processes in affected lungs promote commitment of
progenitors into non-regenerative cell phenotypes, such
as pathological macrophages or myofibroblasts. Lung
during inflammation and fibrosis is characterized by dis-
tinct and stage-specific expression pattern of chemokines,
cytokines, growth factors, and extracellular matrix struc-
ture, creating a specific pulmonary signalling milieu [1].
As previously reported, lungs of bleomycin-instilled mice
show elevated levels of chemokines and pro-inflamma-
tory cytokines one week after the bleomycin challenge,
and prominent production of pro-fibrotic mediators,
including TGF-b pulmonary fibrosis [12]. Our results
demonstrate that individual cytokines in vitro and the
stage-specific signalling in the lung determine the fate of
multilineage progenitor cells. Our observations are in
line with studies on irradiation-induced lung inflamma-
tion demonstrating that mesenchymal stem cells injected
at early phase of lung injury differentiate into epithelial
and endothelial cells, while those injected at a late stage
acquired aSMA+ myofibroblast phenotype [25]. Thus, we
hypothesize that in mouse model of bleomycin-induced
pulmonary fibrosis, progenitor cells become activated
upon injury, however, the signalling in the affected lung
promotes formation of non-regenerative cell phenotypes.
Furthermore, our results showed that administration
of prominin-1+ progenitors only 2 hours after bleomycin
instillation prevents pulmonary fibrosis development.
Instead, transplantation of prominin-1+ progenitors dur-
ing ongoing inflammation or fibrogenesis fails to attenu-
ate disease progression. Of note, anti-inflammatory
effects of mesenchymal stem cells were only observed
when delivered immediately after bleomycin instillation
[16,26,27]. We therefore suggest that lineage commit-
ment induced by inflammatory and fibrotic environment
can explain these observations. Accordingly, it is concei-
vable that differentiating cells produce less anti-inflam-
matory factors, such as nitric oxide for example, and
lose their anti-inflammatory properties. However, we
cannot exclude that efficient attenuation of ongoing
inflammation or fibrosis requires simply higher number
of transplanted cells for an adequate response.
In this study we demonstrated that bone marrow-derived
cells, and in particular, prominin-1+ progenitors represent
one of the cellular sources for myofibroblasts in bleomy-
cin-induced experimental pulmonary fibrosis. Our data are
in line with a previous report showing the formation of
bone marrow-derived fibroblasts in lungs of chimeric mice
in response to bleomycin challenge [7]. Furthermore, bone
marrow-derived fibroblasts and myofibroblasts have been
found in other models of pulmonary disorders including
irradiation-induced lung fibrosis [6], asthma [28], broncho-
pulmonary dysplasia [29], and even after paracetamol treat-
ment [30]. So far, collagen I-producing CD45+ circulating
fibrocytes have been identified as an important cellular
source for myofibroblasts of hematopoietic origin [31].
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Figure 7 Prominin-1+ cells expanded from lungs of bleomycin-treated mice fail to acquire phenotype of type II alveolar epithelial
cells. Seven days after treatment with bleomycin, lungs with ongoing inflammation of C57Bl/6 mice were dissected and prominin-1-positive
cells were isolated using magnetic cell sorting and cultured in the culture expansion medium (CEM) for 2-3 weeks. Expanded cells showed a
round, semi-adherent phenotype, were positive for prominin-1, CD45, CXCR4, c-kit, and mostly negative for F4/80, SP-C and fibronectin (A).
Further, sorted prominin-1+ cells were stimulated for different lineage differentiation. In the presence of TGF-b prominin-1+ progenitors formed
fibronectin-positive cells and up-regulated myofibroblast-specific mRNA levels: Fn1, Col1a1 and Acta2 (B). Bars represent mean ± SD from at least
5 individual cell cultures. Addition of M-CSF to cultures resulted in formation of E.coli phagocytising F4/80-positive cells (C). Prominin-1+ cells
derived from inflamed lungs cultured in the SAGM for 14 days failed to produce SP-C at protein and mRNA levels (D). Abbreviations: ctr prom-1-
prominin-1+ cells isolated from healthy lung, BLM-prom-1- prominin-1+ cells isolated from the inflamed lung 7 days after bleomycin instillation.
DAPI visualized cell nuclei. Bars = 20 μm. (**) - p < 0.01, (***) - p < 0.001.
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Prominin-1+ cells share features of fibrocytes, such as
expression of CD45, CXCR4, but are negative for collagen
I and CD34, and therefore clearly represent a distinct cell
population
Our data further point to central role of TGF-b path-
way in conversion of prominin-1+ cells into pathological
myofibroblasts. This is not surprising, because TGF-b
has been implicated in different fibrogenic processes in
the lung. For example, organ-specific over-expression of
TGF-b in the lung of adult mice is sufficient to induce
pulmonary fibrosis [32]. On the cellular level, TGF-b
signalling not only promotes myofibroblast lineage com-
mitment, but also induces epithelial-to-mesenchymal
transition of alveolar epithelial cells [33]. On the mole-
cular level, TGF-b stimulates the synthesis and deposi-
tion of collagen I [2]. In our model, TGF-b signalling
mediated the phosphorylation of Smad2 proteins, point-
ing to the involvement of canonical Smad-dependent
signalling pathways [34,35] in the transition of progeni-
tors into myofibroblasts.
Multipotent nature and uncontrollable in vivo lineage
commitment of stem and progenitor cells raised serious
questions about the safety of stem cell-based therapies
against IPF. Furthermore, our findings highlight the need
for careful evaluation of cells isolated from injured organs
for cell-based therapies. It remains to be determined
whether these mechanisms are specific for bone marrow-
derived cells or affect also the function of “true” pulmon-
ary epithelial stem and progenitor cells. Recently, it has
been reported that transplantation of alveolar type II cells
improves outcomes in bleomycin-induced fibrosis irre-
spective of the disease stage [36]. This finding opts for
use of committed or differentiated cells in cell-based
regenerative approaches. However, an attractive alterna-
tive is targeting stem and progenitor cells naturally resid-
ing in the affected lungs, in order to inhibit their
contribution to pathological processes and even to re-
activate their regenerative potential. Thus, hematopoietic
stem and progenitor cells represent a powerful tool in
regenerative medicine. However, in-depth understanding
of stem cell biology and the nature of hematopoietic cells
are required for successful cell-based therapy against IPF.
Conclusions
Herein, we provide evidence that the pro-fibrotic microen-
vironment suppresses the regenerative capacity of promi-
nin-1+ progenitor cells, and instead promotes their
differentiation into pathological myofibroblasts and
macrophages. Furthermore, we show that prominin-1+
progenitor cells derived from healthy or inflamed lung tis-
sues differ in their regenerative capability. Therefore, we
concluded that the microenvironment of injured lung tis-
sue dictates the fate and function of bone-marrow-derived
cell progenitors, which may either support pathological
remodelling or actively contribute to regeneration in the
lungs. Thus, our findings highlight the need for careful
evaluation of cells isolated from injured organs for cell-
based therapies.
Additional material
Additional file 1: Additional methods and figure legends. The file
contains the additional methodological information and the figure
legends to the additional figures S1-S5.
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